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Abstract 
Multiple myeloma is caused by abnormal plasma cells that accumulate in the bone marrow and 
interact with resident cells of the bone microenvironment to drive disease progression and 
development of an osteolytic bone disease. Bone marrow adipocytes (BMAds) are emerging as 
having important endocrine functions that can support myeloma cell growth and survival. 
However, how BMAds respond to infiltrating tumour cells remains poorly understood. Using the 
C57BL/KaLwRij murine model of myeloma, bone marrow adiposity was found to be increased in 
early stage myeloma with BMAds localising along the tumour-bone interface at later stages of 
disease. Myeloma cells were found to uptake BMAd-derived lipids in vitro and in vivo although, 
lipid uptake was not associated with the ability of BMAds to promote myeloma cell growth and 
survival. However, BMAd-derived factors were found to increase myeloma cell migration, 
viability and the evasion of apoptosis. BMAds are a major source of adiponectin, which is known 
to be myeloma-suppressive. Myeloma cells were found to down-regulate adiponectin specifically 
in a model of BMAds, but not in white adipocytes. The ability of myeloma cells to down-regulate 
adiponectin was dependent at least in part on tumour-derived TNF-alpha. Collectively our data 
support the link between increased bone marrow adiposity and myeloma progression. By 
demonstrating how myeloma cells release TNF-alpha to down-regulate BMAd-derived 
adiponectin, we reveal a new mechanism by which myeloma cells alter the bone microenvironment 
to support disease progression. 
 
Keywords: multiple myeloma, bone marrow adipose tissue, adipocyte, adiponectin, cancer  
3 
 
Introduction 
Multiple myeloma is an incurable haematological malignancy associated with clonal expansion of 
plasma cells within the bone marrow and the development of lytic bone disease. For many years 
it has been recognised that the success of myeloma cells to thrive within the bone marrow is in 
part due to their ability to interact favourably with the bone microenvironment. Myeloma cells can 
influence their neighbouring bone cells, resulting in bone destruction and  the release of growth 
factors into the local environment that can be utilised by the myeloma cells for growth and survival, 
a process often referred to as the vicious cycle (1). However, the influence that myeloma cells have 
on other non-bone resident cells in the bone marrow is less clear. One of the most abundant cell 
types in the bone marrow is the adipocyte, these cells account for up to 70% of bone marrow 
volume in adult humans (2). Once thought of as inert space filling cells, adipocytes are now 
recognised as having specialised functions (3). These cells not only store energy in the form of 
triglycerides but also secrete important adipokines such as leptin and adiponectin. For many 
decades, bone marrow adipocytes (BMAds) were very much understudied and underappreciated. 
However, in recent years, this has changed, as their roles in metabolism (4) and cancer have started 
to emerge. BMAds have been implicated in cancers that metastasize to bone, such as prostate (5, 
6) and breast cancer (7), as well as cancers that first become established in bone, such as acute 
myeloid leukaemia (8) and myeloma (9-13), where they appear to have a supporting role in fuelling 
cancer growth and progression and bone disease. However, the mechanisms driving this 
relationship remain unclear.  
BMAds are thought to contribute to bone homeostasis via the bioactive molecules they secrete, 
leading to the activation of numerous signalling pathways in many different cell types by means 
of autocrine, paracrine and endocrine signalling (14). BMAds differ in their secretory profiles from 
4 
 
both white and brown adipocytes. Furthermore, they have been shown to up-regulate different 
genes when in close proximity to prostate cancer cells in comparison to subcutaneous adipocytes, 
suggesting that they have bone specific effects (5). Adiponectin is the most prevalent adipokine 
secreted by adipocytes. While adiponectin is secreted by all adipose cells, it is most highly secreted 
by BMAds (4, 15). Adiponectin is known to play an important role in insulin sensitivity and fatty 
acid oxidation and has been shown to have anti-tumour effects (16-18). Adiponectin is 
paradoxically decreased during conditions of elevated adiposity, and our previous studies have 
implicated both obesity and hypoadiponectinaemia in the progression of multiple myeloma and its 
associated bone disease (19-21). In the present study, we have investigated how myeloma cells 
alter BMAd biology in order to circumvent the tumour-suppressive effect of adiponectin. 
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Materials and Methods 
Animal model 
Animal experiments were undertaken under UK Home Office Project License 30/2996. Animals 
were housed in individually ventilated cages in the Department of Biomedical Services, University 
of Oxford, with access to normal chow and water ad libitum. Studies were conducted using age-, 
sex-, and weight-matched KaLwRij mice (Harlan Netherlands). Due to the nature of the model the 
speed of tumour development can vary between individual experiments. As such, ‘low’ and ‘high’ 
tumour burden, indicating less than an average of 10% myeloma cells in bone marrow or greater 
than an average of 30% myeloma cells in bone marrow respectively, was used to describe the 
experimental conditions, rather than days after inoculation. Mice were inoculated with 106 
5TGM1-GFP cells or PBS vehicle control by intravenous injection. Mice were sacrificed on day 
16 to represent ‘low’ tumour burden and day 23 to represent ‘high’ tumour burden post inoculation 
(5 controls, 7-low and 6-high tumour burden mice were used, all animals were 12 weeks of age). 
Investigators were not blinded throughout the experiment. In separate experiments, animals used 
for osmium tetroxide analysis were inoculated as above and culled on day 24 when tumour burden 
was less than 10%, representing a ‘low’ tumour burden model (4 controls and 5 inoculated, all 
animals were 8 weeks of age). Investigators were blinded at endpoint. Animals used for bone 
marrow plug analysis were inoculated as above and culled on day 23 (3 inoculated, animals were 
6 months of age to ensure adequate visualisation of BMAds, all mice had detectable myeloma). 
To investigate the effect of the JJN-3 human cell-line in vivo age-, sex-, weight-matched Nod/Scid 
γ (NSG, NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ) mice were purchased from Charles River. Mice 
were inoculated with 106 JJN-3 cells or PBS vehicle control by intravenous injection. Animal were 
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sacrificed on day 23. (5 controls and 7 inoculated, all animals were 8 weeks of age). Investigators 
were not blinded throughout the experiment. 
Immunofluorescence  
Sections from paraffin-wax-embedded tissue samples were de-waxed, and antigen retrieval was 
performed using citric acid buffer. Sections were incubated with 1:200 chicken anti-GFP 
(Invitrogen A10262) and 1:100 rabbit anti-perilipin (Cell Signaling 3470S) in 1% BSA/5% 
serum/phosphate buffered saline (PBS) overnight at 4°C. Sections were subsequently incubated 
for 1 hr at room temperature with 1:200 Alexa Fluor 488 anti-chicken (Invitrogen A11039) and 
Alexa Fluor 568 anti-rabbit secondary antibodies (Invitrogen A11011), and 1:5000 DAPI. Lipid 
uptake studies using patient samples were performed by layering the bone marrow sample over 
histopaque and centrifuging at 400 x g for 30 minutes. The fatty top layer of the sample was then 
removed and diluted 1:2 with normal media, myeloma cells were then added for 24 hrs before 
staining. The lipid uptake studies using cell lines were performed by liberating the lipids from 
ST2-derived BMAds and incubating them with myeloma cells for 24 hrs. Cells were then stained 
with 1:1000 BODIPY (ThermoFisher Scientific D3922) or 1:500 Lipidtox (ThermoFisher 
Scientific H24476) and 1:2000 Hoechst (Sigma B2261) and visualised by confocal microscopy. 
Bone marrow plugs 
Marrow plugs were prepared using femurs taken from 6 month old mice that had been inoculated 
with 5TGM1-GFP cells for 23 days. Marrow plugs were extracted and fixed on slides (22). The 
samples were then washed with PBS and stained using 1:500 Lipidtox (ThermoFisher Scientific 
H24476) for 30 minutes. 
Quantification of tissue sections 
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Long bones were formalin-fixed, decalcified in 14% EDTA, paraffin-embedded, and sectioned 
along the mid-sagittal plane in 4-µm-thick sections prior to staining with haematoxylin and eosin. 
Histomorphometric analysis was performed to quantify BMAd number and tumour burden using 
Osteomeasure histomorphometry software as previously described (23) or ImageJ software.  
Osmium tetroxide staining 
Formalin fixed, decalcified tibiae were washed in Sorensen's Phosphate buffer (81 mM KH2PO4, 
19 mM Na2HPO4 ⋅ 7H2O, pH 7.4) and stained with 1% osmium tetroxide solution (2% w/v; Agar 
Scientific, UK - diluted 1:1 in Sorensen's Phosphate buffer) for 48 hrs at room temperature, 
washed, and stored in Sorensen's Phosphate buffer at 4 °C. Stained tibiae were arranged in parallel 
in 1% agarose in a 30-mL universal tube and mounted in a Skyscan 1172 desktop micro CT 
(Bruker, Kontich, Belgium). The samples were then scanned through 360° using a step of 0.40° 
between exposures. A voxel resolution of 12.05 μm was obtained in the scans using the following 
control settings: 54 kV source voltage, 185 μA source current with an exposure time of 885 ms. A 
0.5-mm aluminium filter and two-frame averaging were used to optimize the scan. After scanning, 
the data were reconstructed using Skyscan software NRecon v1.6.9.4 (Bruker, Kontich, Belgium). 
The reconstruction thresholding window was optimised to encapsulate the target image. 
Volumetric analysis was performed using CT Analyser v1.13.5.1 (Bruker, Kontich, Belgium) (24). 
Cell culture and adipocyte differentiation 
The 5TGM1-GFP and JJN-3 myeloma cell lines were cultured in RPMI media supplemented with 
10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM Sodium Pyruvate, 0.1 mM Non-
Essential Amino Acids, and 100 U/ml Penicillin-Streptomycin antibiotic, and incubated at 37°C 
with 5% CO2. ST2 cells were seeded in RPMI media (supplemented as above) in 6-well plates at 
a density of 8x105 per well. After 24 hrs the media was changed to adipogenic media containing 
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0.5 mM IBMX, 0.25 µM dexamethasone and 10 µg/ml insulin. Cells were then incubated for 3 
days, after which the media was changed to maintenance media containing insulin alone, and cells 
were then incubated for a further 3 days. Media was then changed to normal RPMI media and 
incubated for 24 hrs before the cells were used. Human bone marrow stromal cells (BMSCs) were 
grown in DMEM containing 20% FBS. Upon reaching 70% confluency, culture media was 
changed for adipogenic media (DMEM + 10%FBS) containing 0.5 mM IBMX, 1 µM 
dexamethasone, 100 nM insulin and 0.2 mM indomethacin. Media was replenished every 3 days 
for 21 days. Media was then changed to RPMI and cells were incubated for 24 hrs before use. Cell 
differentiation was confirmed using Oil red O staining according to the manufacturer’s 
instructions. Co-culture experiments were carried out using transwell inserts (Scientific 
Laboratory Supplies 353090) which were added to the plates after the differentiation process. 
Myeloma cells were then plated in the inserts at a density of 1.5x106 and left for 24, 48 or 72 hrs.  
Lipid Uptake Studies 
Myeloma cells were treated with limiting growth media (RPMI with no glucose or supplements) 
for 24 hrs. Cells were then treated with a 1:1 mix of limiting growth media, limiting growth media 
and normal media, limiting growth media and BMAd-derived lipid or limiting growth media and  
BMAd 24 hr conditioned media, for a further 24 hrs. BMAd-derived lipid was liberated by 
scraping the BMAd cells and then centrifuging them at 17,000g for 5 minutes. The white lipid 
layer was then removed from the top of the media. 150 μl of lipid was added to 600 ul of limiting 
growth media to make up the BMAd lipid mixture. BMAd conditioned media was media incubated 
with BMAds for 24 hrs. Cells were then seeded in a 96-well plate for Alamar Blue analysis or in 
confocal dishes for visualisation. 
Oil Red O Quantification 
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Oil red O stain was eluted using 1ml of isopropanol for 10 minutes. The absorbance of the elution 
was measured at a wavelength of 518nm. Eluted stain from undifferentiated ST2 cells was used as 
a blank.  
Viability assay 
Myeloma cells were seeded in normal RPMI media as described previously at a density of 
7.5x105/ml in transwell inserts alone or in co-culture with undifferentiated BMSCs or BM-like 
adipocytes derived from ST2 cells. Cells were re-plated in a 96 well plate at each time point. 10% 
Alamar Blue was added and cells were incubated for 3 hrs. Fluorescence intensity was measured 
using a FLUOstar omega plate reader. 
Migration assay 
Boyden chambers (Costar 3422) were used according to the manufacturer’s instructions. The lower 
chambers contained either 800 µL normal media, 50% conditioned media taken from 
undifferentiated ST2 BMSCs (control), or 50% conditioned media from adipocytes derived from 
ST2 cells. Cells were seeded in the top chamber at a density of 4x105 in 200 uL of 1% FBS media. 
After 24 hrs viability of the cells in the lower chamber was measured using Alamar Blue.  
Patient samples 
Serum samples from patients with multiple myeloma, and the respective age- and sex-matched 
controls (n=20, 15M, 5F, age 62.95 years ± 10.7), were obtained through collaboration with MTD 
and with approval from the Institutional Review Board and Biospecimen Protocol Review Group 
of the Mayo Clinic College of Medicine. All patients were newly diagnosed myeloma patients (M-
Spike 2.61g/dL ± 1.99 g/dL, 12/15 patients had evidence of bone disease as indicated by 
osteoporosis and or lytic lesions or fracture. Bone marrow samples from patients with, or under 
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investigation for, myeloma were obtained with the approval of the Oxford Clinical Research Ethics 
Committee (09/H0606/5+5 project 16/A185). 
QPCR 
RNA from cell lines and primary BMSCs was isolated using the RNeasy kit (QIAGEN). cDNA 
was generated using Precision Reverse Transcription Premix kit (Primerdesign). Mouse 
adiponectin was detected by real-time PCR using Sybr green primers (Life Tech). Relative gene 
expression of adiponectin was normalized to gene expression for Gapdh (Life Tech). Primer 
sequences: mAdiponectin F: AGACCTGGCCACTTTCTCCTCATT; mAdiponectin R: 
AGAGGAACAGGAGAGCTTGCAAGA; mGAPDH F: TCAACAGCAACTCCCACTCTTC 
CA; mGAPDH R: ACCCTGTTGCTGTAGCCGTATTCA. QuantiTech Primers for Adipsin, 
Visfatin and Resistin were purchased from Qiagen and used according to the manufacturer’s 
instructions. 
Immunoblotting and ELISA 
Immunoblotting was used to measure apoptosis and adiponectin expression following a standard 
Bio-Rad protocol. The primary antibodies used were 1:1000 rabbit anti-cleaved PARP (Cell 
Signaling 5625), 1:1000 rabbit anti-cleaved caspase-3 (Cell Signaling 9664), 1:1000 rabbit anti-
adiponectin (Abcam ab3455) 1:1000 rabbit anti-phospho-c-Jun N-terminal kinases (p-JNK; 
Thr183/Tyr185) (Cell signaling 9251), 1:1000 rabbit anti-total JNK (T-JNK) (Cell signaling 
9252), 1:1000 rabbit anti-phospho-p38 mitogen-activated protein kinases (p-p38 MAPK; 
Thr180/Tyr182) (Cell signaling 4092), 1:1000 rabbit anti-total p38 MAPK (T-p38 MAPK) (Cell 
signaling 8690), 1:1000 rabbit anti-phospho-p44/42 MAPK [phospho-extracellular signal-related 
kinases 1 and 2 (p-ERK1/2); Thr202/Tyr204] (Cell signaling 9101), 1:1000 rabbit anti-total p44/42 
MAPK (T-ERK1/2) (Cell signaling 9102), and 1:10,000 mouse anti-β actin (Sigma A5316). All 
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secondary antibodies were purchased from Cell Signaling. An ELISA was used to measure 
adiponectin (R&D systems MRP300) and TNF-α (R&D systems MHSTA50) according to the 
manufacturer's instructions. 
mRNA Stability Assay 
ST2 derived BMAds were treated with recombinant TNF-α for 24 h, 10μg/ml of Actinomycin D 
was then added, cells were collected at 0, 1, 2, 4 and 6 h following treatment. Levels of adiponectin 
gene expression was measured using qPCR. 
TNF-α neutralisation 
Cytokine blocking was achieved using an antibody directed against mouse TNF-α (R&D Systems 
MAB4101). Co-cultures of myeloma cells and mature adipocytes were treated with anti-TNF-α at 
a concentration of 1.5 µg/ml, or isotype control. Treated cells were left for 24 hrs (5TGM1) or 48 
hrs (JJN-3) before conditioned media and RNA were collected. 
Statistical Analyses 
Statistical significance was determined using a Mann-Whitney U Test, Unpaired t-test, Pearson 
correlation or one-way ANOVA and TUKEY-Kramer posthoc test. Significance was considered 
for p<0.05. Datasets from in vivo analysis were based on groups of animals.  In vitro experiments 
were performed a minimum of three separate occasions. Data are represented as mean ± SE unless 
otherwise stated. 
 
 
  
12 
 
Results 
Bone marrow adiposity is increased in early stage myeloma. 
To investigate the effect of myeloma cells on BMAd localisation and number, the well-established 
Radl model of myeloma was used (25, 26). This model successfully recapitulates human disease 
with 5TGM1 cells homing to bone where they become established and cause bone lesions (27, 28). 
First we analysed KaLwRij mice with low tumour burden using osmium tetroxide staining of their 
tibiae (Figure 1A). These mice had significantly higher bone adiposity compared to controls 
(Figure 1B), and this increase in adiposity was primarily confined to the distal tibia, suggesting 
that the increase is within the constitutive BMAd population (29). We did not observe any changes 
in the adipocytes that reside in the proximal tibia, although this may reflect the sensitivity of 
osmium-tetroxide based detection. To investigate this further, mice were culled 16- and 23-days 
post inoculation to mimic low and high tumour burden, reflecting early and late-stage disease. 
Immunofluorescence of the femurs confirmed the presence of GFP-positive tumour cells (denoted 
by white line), as well as identifying BMAds morphologically using adipocyte marker, perilipin 
(Figure 1C, Supplemental Figure 1). We observed that the BMAds present in the 23-day mice were 
predominantly located along the tumour-bone interface (Figure 1C, red dotted line), with a change 
in the ratio of BMAds outside the tumour area:within the tumour area from 9:1 in the low tumour 
burden mice to 1:1 in the high tumour burden mice (Figure 1D).  Similar localisation of BMAds 
along the tumour-bone interface was observed in a JJN-3 model of myeloma (Supplemental Figure 
2). Paraprotein levels and tumour burden were significantly higher in the mice with high tumour 
burden compared to low (Figure 1E and F), indicating significant disease progression from less 
than 10% plasma cells within the bone marrow to greater than 30% marrow infiltration. The 
number of BMAds present in low tumour mice was significantly higher in plasma-cell inoculated 
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mice than compared to control. However, this increase was not observed in the high tumour mice 
(Figure 1G).  
BMAds support myeloma growth by a lipid-independent mechanism 
Our discovery that myeloma cells promote an increase in the number of BMAds at early stages of 
disease in vivo, combined with previous studies suggesting that BMAds are supportive of myeloma 
growth (9, 30), led us to consider how BMAds can confer a survival advantage to myeloma cells. 
Our studies confirm the myeloma-supportive effects of BMAds, with a significant increase in 
myeloma cell viability and decrease in apoptosis when myeloma cells were cultured with either 
BMAds or BMSCs, and an increase in migration towards media conditioned from BMAds (Figure 
2A - D).  
BMAds are a major source of lipid, and prostate cancer cells are known to uptake adipocyte 
derived lipids to promote cell viability (5). This led us to investigate whether myeloma cells behave 
in a similar manner. Visualisation of lipid droplets demonstrated that JJN-3 myeloma cells were 
able to uptake lipids isolated from the bone marrow of patients with myeloma (Figure 3A). 
However, when JJN-3 or 5TGM1 myeloma cells were incubated with liberated lipid droplets from 
BMSCs or BMAds, the amount of lipid uptake was significantly different between the myeloma 
cells, with limited lipid uptake detected in 5TGM1 myeloma cells (Figure 3B, C and D). Next, we 
investigated whether lipid uptake had a positive effect on myeloma cell viability. There was no 
difference in viability between JJN-3 or 5TGM1 myeloma cells that had been incubated with or 
without BMAd-derived lipid (Figure 3E). Cells were then placed under metabolic stress to 
establish whether by inducing a stress response, they may utilise lipid for survival.  Myeloma cells 
were grown in limiting condition media (RPMI with no glucose, supplements or FBS) for 24 hrs 
and then incubated with liberated lipid or conditioned media from BMAds. Interestingly, the 
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culture of myeloma cells in limiting conditions resulted in the appearance of lipidtox-positive cells, 
indicative of de novo lipogenesis (Figure 4A). A trend towards increased viability was observed 
when myeloma cells were cultured in limiting conditions and then exposed to BMAd-derived lipid. 
However, conditioned media taken from BMAds was found to significantly increase viability 
compared to both the control and the BMAd-derived lipid (Figure 4B). To determine whether lipid 
is present within myeloma cells in vivo, we used a technique to visualise the bone marrow by 
extracting fresh marrow with a needle and fixing and staining it immediately (22). Using this 
technique, we were only able to detect the presence of lipid in a very small number of 5TGM1-
GFP cells present in the bone marrow in vivo (Figure 4C and Supplemental figure 3). Furthermore, 
it is not possible to conclude whether these lipid droplets were from neighbouring BMAds or a 
product of de novo lipogenesis.  
Myeloma cells down-regulate adiponectin in BMAds 
Our studies reveal a myeloma-promoting effect of BMAds that does not appear to be related to 
lipid uptake. To reconcile our findings that BMAds are increased and protect myeloma cells 
despite the known tumour-suppressive effects of adiponectin (16), we investigated whether 
myeloma cells down-regulate adiponectin in BMAds. Quantitation of circulating adiponectin 
revealed a significant reduction in adiponectin in patients with multiple myeloma, and in myeloma-
bearing mice (Figure 5A and B). Co-cultures of myeloma cells with BMSCs or BMAds 
demonstrated that adiponectin was significantly down-regulated in the ST2-derived BMAds that 
had been co-cultured with myeloma cells as compared to BMAds cultured with media alone. This 
was observed in both cell lysates and CM at the protein level (Figure 5C and D) as well as at the 
RNA level (Figure 5E). To further confirm the down-regulation of adiponectin in BMAds, primary 
myeloma cells were co-cultured with ST2-derived BMAds (Figure 5F), again showing a decrease 
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in adiponectin levels following 24 hrs of co-culture. This reduction was not observed after 72 hrs 
in the cell lysates, however, this may be a reflection of low primary cell viability after 72 hrs of 
culture. Similar experiments were performed using 3T3-L1 adipocytes. Adiponectin secretion was 
lower in 3T3-L1 adipocytes than in ST2-derived BMAds, confirming that the former are more 
WAT-like. (Supplemental Figure 4A), However, unlike in ST2-derived BMAds, myeloma cells 
did not further decrease adiponectin expression in 3T3-L1 adipocytes, suggesting that the ability 
of myeloma cells to down-regulate adiponectin is specific to BMAds (Supplemental Figure 4B).  
Myeloma cells down-regulate adiponectin in BMAds via TNF-a 
Our data demonstrates that myeloma cells down-regulate adiponectin in BMAds. However, the 
mechanism behind this down-regulation remains unknown. Co-culture of myeloma cells with 
BMAds, either in direct contact or separated by a transwell membrane, was found to have a modest 
effect to reduce BMAd number and size (Figure 6A-F). Investigation of additional adipokines did 
not reveal a generalised loss in adipokine secretion, with no significant difference in expression of 
resistin, visfatin or adipsin (Figure 6G). This suggests a specific mechanism underlying the down-
regulation of adiponectin in BMAds by myeloma cells. Myeloma cells secrete a number of 
cytokines known to drive disease progression, one of which is TNF-alpha (31, 32). Measurement 
of TNF-α in the bone marrow plasma of myeloma-bearing mice demonstrated a significant 
correlation with tumour burden, confirming an association with disease progression (Figure 7A). 
Previously TNF-α has been implicated as a potential regulator of adiponectin expression in WAT, 
but not in the context of cancer (33-35). Transwell co-culture of myeloma cells with BMAds was 
found to increase activation of JNK, p38MAPK and ERK1/2, pathways which have previously 
been implicated in TNF-a-mediated suppression of adiponectin in WAT (36) (Figure 7B). TNF-α 
treatment alone did not induce theses changes in BMAds suggesting that WAT may be more 
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sensitive to TNF-α alone. To determine whether TNF-α could regulate adiponectin in BMAds, we 
treated ST2-derived bone marrow BMAds with mouse recombinant TNF-α. After 24 hrs and 48 
hrs, there was a 65% and 50% respective decrease in Adipoq expression (Figure 7C) and in secreted 
adiponectin (Figure 7D). A smaller reduction in Adipoq expression (41%) was observed after 72 
hrs suggesting a level of recovery from the initial TNF-α exposure. TNF-a treatment also resulted 
in a significant difference in Adipoq mRNA stability following 2hrs treatment with the 
transcriptional inhibitor actinomycin D, but no overall change in mRNA half-life (Supplemental 
Figure 5). The addition of recombinant TNF-α to mature BMAds cultures for 72 hrs also caused a 
reduction in Oil Red O staining indicating a decreased in BMAd number in a similar manner to 
myeloma/BMAd co-culture (Figure 7E). To determine whether the down-regulation of 
adiponectin was due to myeloma-derived TNF-α, a TNF-α blocking antibody was used. 
Adiponectin secretion (Figure 7F-G) and Adipoq expression (Figure 7H and Supplemental Figure 
6A) were decreased in co-cultures containing either 5TGM1 or JJN-3 myeloma cells alone or in 
the presence of an isotype control antibody. In contrast, addition of a neutralizing antibody to TNF-
a to myeloma/BMAd co-cultures had no effect on viability (Supplemental Figure 6B) but blocked 
the suppression of adiponectin and prevented the reduction in BMAd number (Figure 7I and 
Supplemental Figure 6C).  
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Discussion 
There is growing evidence that BMAds play an important role in a number of different cancers 
that metastasise to (breast and prostate), or develop within the bone such as myeloma. Our study 
advances these previous findings by providing a mechanism by which myeloma cells interact with 
BMAds to circumvent the tumour-suppressive effect of adiponectin.  
Using our murine myeloma model, we have shown that in early stage disease (defined clinically 
as less than 10% myeloma cells present within the bone marrow) there is a significant increase in 
marrow adiposity. This is supported by previous studies that revealed that bone marrow from 
patients with myeloma contained increased pre-adipocytes and significantly larger mature 
adipocytes than bone marrow obtained from healthy volunteers, and that adipogenic gene 
expression is elevated in mesenchymal stem cells from myeloma-bearing mice (10, 12). Our data 
shows an increase in overall adiposity volume, which could be due to either increased BMAd size, 
number, or both. This increase may be in response to the initial influx of cancer cells, as it is not 
observed in late disease.  Although, this finding is to be expected, as in end-stage disease the 
myeloma cells have substantially increased in number and both modulate bone cell numbers and 
behaviour, and also physically crowd out other cells within the bone marrow microenvironment. 
Therefore, the observed change in ratio from BMAds localised outside the tumour area to BMAds 
inside the tumour area in the high tumour-bearing mice may be a simple reflection of increased 
tumour burden. However, interestingly the remaining BMAds were shown to be lining the tumour-
bone interface suggesting that BMAd localisation is affected by the infiltrating tumour cells. 
Whether these BMAds are recruited by the tumour cells, whether BMAds within the tumour area 
are destroyed by the infiltrating tumour cells leaving only the cells surrounding the tumour, or 
whether the remaining BMAds shrink in size but persist in the marrow, remains unclear. Our in 
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vitro studies demonstrate a small reduction in BMAd number and size following culture with 
myeloma cells, supporting our in vivo findings in late-stage myeloma. The initial increase in 
adiposity that we observed suggests that BMAds have a positive impact on disease progression. 
An intriguing finding was that the increase in adiposity appeared most prominently in the distal 
section of bone. BMAds are proposed to exist in two broad sub-types; regulated and constitutive. 
Regulated BMAds are found in the more metabolically active regions of the bone and are thought 
to be responsible for responding to environmental cues such as changes in diet or exercise. 
Constitutive BMAds develop early in life and are rarely depleted, and are thought to be less 
responsive than regulated (3). However, in our study, we identified an increase in marrow adiposity 
in the distal tibia, the site at which constitutive BMAds reside. One possibility is that myeloma 
does impact the regulated BMAds but that, in our model these cells remain too diffuse to be 
detectable by osmium tetroxide staining. Indeed, KaLwRij mice are a sister strain of the B6 mouse 
which have low levels of regulated fat until later in life (29). At younger ages, as in our mice, 
regulated BMAds are dispersed among hematopoietic cells, whereas constitutive BMAds are 
clustered together resembling the tightly packed structure of adipocytes in WAT. As such, our 
findings in the distal tibia might reflect, the sensitivity of the osmium staining for detection of 
clusters of BMAds as opposed to single cells. If so, in our model, changes in regulated BMAds 
within the metaphyseal region may be below the level of detection using this approach. It is also 
possible that early changes occur in regulated BMAds residing close to the constitutive region, but 
that these changes are too subtle to detect. Alternatively, it may be that myeloma cells modify only 
the constitutive BMAds. It must also be acknowledged that a limitation of the study is that 
histological analysis was performed on femurs and osmium tetraoxide on tibiae, and it is of interest 
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to determine whether changes in constitutive BMAds are also observed in femoral bone. Formally 
addressing these questions in future studies is warranted. 
Our findings also provide evidence to support the growing belief that BMAd interactions are 
advantageous for myeloma cell viability and evasion of apoptosis, and that adipogenic factors 
promote myeloma cell migration (9-11). Interestingly, we also observed that BMSCs offer a 
significant level of support in promoting viability and evading apoptosis, this raises the question 
as to the similarities between these two cell types and the factors they secrete. In contrast, BMAds 
significantly increased the migration rates of myeloma cells compared to BMSCs. This is in line 
with other studies in different tumour types that have a propensity to metastasise to bone, one study 
showed that breast cancer cells have increased migration towards human bone tissue-conditioned 
medium (7), and another that prostate cancer cells interact with BMAds resulting in the promotion 
of growth and invasiveness driven by BMAd-derived lipids from nearby BMAds (5). These 
observations raise the questions as to whether myeloma cells are attracted to factors secreted by 
BMAds, or whether myeloma cells need to utilise the BMAd’s lipid storage in a manner similar to 
prostate tumour cells or whether both elements are important. We have shown that conditioned 
media rich in BMAd-derived factors promotes myeloma cell growth and migration. Furthermore, 
we have also shown that myeloma cells are capable of BMAd-derived lipid uptake in vitro, 
however, striking differences were found between myeloma cell lines. Interestingly we did not 
observe a difference in viability when liberated BMAd-derived lipid was added to normal culture 
media. However, we did observe a trend towards elevated viability when myeloma cells were 
cultured in growth-limiting conditions, and then liberated lipid was added, suggesting that lipids 
may be utilised in times of stress. In addition, growth-limiting conditions alone induced de novo 
lipogenesis in myeloma cells, suggesting a selective dependence upon exogenous lipid as an 
20 
 
energy source that warrants further investigation. In vivo, the presence of lipid was detectable in a 
small proportion of myeloma cells in the bone marrow of myeloma-bearing mice. While it is not 
possible to distinguish between lipid uptake and de novo lipogenesis in vivo, the small proportion 
of myeloma cells with detectable lipid may suggest a limited role for lipid in myeloma growth in 
the bone marrow. Notably, while there is a marked difference in lipid uptake between 5TGM1 and 
JJN-3 myeloma cells in vitro, the in vivo preclinical models are strikingly similar with respect to 
tumour burden and osteolytic bone disease. Furthermore, we show that localisation of BMAds 
along the tumour-bone interface is comparable between models. Taken together, our data suggests 
a limited role for lipid uptake in disease pathogenesis. Future studies are needed to elucidate 
whether lipids supply valuable energy for cell motility and/or invasiveness, or whether they may 
play a direct role in conferring a level of drug resistance.  
Most research in the adipocyte-cancer field implicates the adipocyte as a cell that promotes tumour 
growth. However, adipocytes do not only secrete tumour-promoting factors. One adipokine known 
to have potent anti-tumour effects is adiponectin, the most highly expressed adipokine in the WAT. 
However, low adiponectin levels are associated with a variety of disorders including coronary 
heart disease (37), type 2 diabetes (38, 39), obesity and cancer (40). Interestingly, a number of 
these conditions have also been associated with high levels of TNF-α (41-43). Patients with 
myeloma were shown to have significantly higher levels of TNF-α compared to healthy volunteers, 
with levels rising in association with disease progression. (44). Our murine data supports these 
findings, showing that levels of TNF-α also correlate with tumour burden and that mice inoculated 
with myeloma cells also have significantly lower adiponectin levels. These findings extend our 
previous studies, where we found that adiponectin was reduced in myeloma-permissive mice (16).  
However, the mechanism(s) that links these two proteins in the development of myeloma is 
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unknown. TNF-α is known to regulate adiponectin production in WAT. We now show that TNF-
α is able to downregulate adiponectin in ST2-derived BMAds, likely dependent on both 
transcriptional regulation and loss of mRNA stability. More importantly we show that myeloma 
cells are able to manipulate their environment by down-regulating adiponectin in these BMAds, at 
least in part via the secretion of TNF-α. Interestingly, viability was not altered by blockade of 
TNF-alpha, suggesting additional mechanisms may contribute to the effect of BMAds on myeloma 
cell viability. Moreover, the addition of recombinant TNF-α also caused a change in BMAd 
number in a similar manner to myeloma /BMAds co-cultures. This reduction in adiposity may also 
contribute to lower levels of adiponectin, especially in late stage disease as the myeloma cells start 
to over populate the marrow and directly interact with the majority of remaining BMAds. The 
addition of a TNF-α neutralising antibody restored both adiponectin expression levels and BMAd 
number, however, interestingly, viability was not altered by blockade of TNF-α, suggesting 
additional mechanisms may contribute to the effect of BMAds on myeloma cell viability. Elevated 
levels of TNF-α have long been associated with myeloma, and our results provide new insights 
into the mechanisms by which this key inflammatory cytokine promotes myeloma disease 
progression. 
Collectively, our studies provide new insights into the BMAd-myeloma cell interaction in vivo, 
revealing a new mechanism by which myeloma cells alter their microenvironment to support their 
growth. BMAd-derived factors are utilised for growth and survival and in order to fully take 
advantage of this relationship, myeloma cells have developed a valuable mechanism to down-
regulate adiponectin to thereby evade its anti-tumour effects. Future studies are needed to further 
investigate and understand the contribution of BMAd-derived lipids and whether they play a 
significant role in myeloma disease progression. Once thought of as an inert space filling cell, 
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BMAds are slowly emerging as fundamental to disease progression. As society battles against the 
burgeoning obesity epidemic, efforts to more fully understand the implications of increased bone 
marrow adiposity for tumour growth and survival within bone will become increasingly important. 
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Figure legends 
Figure 1. Bone marrow adiposity is increased in early stage multiple myeloma. (A) Osmium 
tetroxide stained tibia analysed in a model of low tumour burden, <10% myeloma cells in bone 
marrow. (B) Total bone adiposity was measured using CT Analyser v1.13.5.1 (Bruker, Kontich, 
Belgium) software (24). (C) Immunofluorescence imaging using anti-GFP and was used to 
visualise the tumour area and BMAd localisation in the femur (white dotted line highlights area of 
tumour, red dotted line denotes tumour-bone interface). (D) Quantitation of BMAd number, inside 
and outside of the tumour area. (E) Paraprotein levels measured by ELISA. (F) Tumour burden 
was calculated using osteometric software. (G) The number of BMAds was counted using 
osteometric software. Data represents the mean (±SE).  
Figure 2. BMAds support myeloma growth and survival. (A) ST2 cell line BMSCs and patient 
derived BMSCs treated with an adipogenic cocktail scale bar - 200μm. (B) Viability of myeloma 
cell lines was measured using Alamar Blue following co-culture with either media alone (NM) 
BMSC’s or BMAds. Results are expressed as fold change relative to control cultures. Cells were 
cultured in normal RPMI media. Data represents the mean (±SE) of three independent 
experiments. Statistical significance was calculated compared to normal media (NM). (C) The 
expression of apoptotic markers was assessed by immunoblotting. (D) Migration was assessed 
using boyden chambers. Cell number in the lower chamber was measured using Alamar Blue. Data 
represents the mean (±SE) of four independent experiments, statistical significance was calculated 
compared to normal media (NM) control.  
Figure 3. BMAds support myeloma cell growth by a lipid-independent mechanism. (A) 
BODIPY 493/503 staining of myeloma patient-derived lipid droplets (green) in JJN-3 cells. Scale 
bar 50 μm. (B) Lipidtox neutral red staining of ST2-derived lipid droplets in JJN-3 cells. Scale bar 
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50 μm. (C) Lipidtox neutral red staining of ST2 derived lipid droplets in 5TGM1-GFP cells. Scale 
bar 50 μm. All microscopy images show a representative image from four independent 
experiments. (D) The percentage of cells exhibiting lipid droplets was calculated using imageJ 
software. Data points represent the mean (±SE) of four independent experiments. (E) Viability 
was measured using Alamar Blue of JJN-3 and 5TGM1 cells following incubation with, normal 
media (NM), NM with supernatant from scraped ST2 BMSCs or NM with ST2 BMAd-derived 
lipid droplets. Data points represent the mean (±SE) of three independent experiments, statistical 
significance was calculated compared to normal media (NM) control.  
Figure 4. Growth limiting conditions induce de novo lipogenesis in myeloma cells. (A) 
Lipidtox neutral red staining of ST2 derived lipid droplets in JJN-3 and 5TGM1 cells cultured in 
limiting conditions and treated with liberated lipids or conditioned media from BMAds. Scale bar 
50 μm. All microscopy images show a representative image from three independent experiments. 
(B) Viability was measured using Alamar Blue. Results are expressed as fold change relative to 
control cultures. Cells were cultured under limiting conditions for 24 hrs followed by the addition 
of BMAd-derived lipid or BMAd conditioned media for a further 24 hrs. Data represents the mean 
(±SE) of four independent experiments, statistical significance was calculated compared to 
limiting media control. (C) Bone marrow plug taken from a 6 month old mouse 23 days post 
inoculation with 5TGM1 myeloma cells.  Immunofluorescence of 5TGM1-GFP (green) cells and 
Lipidtox (red) to visualise adipocytes/lipid. Scale bars 200 μm – 50 μm respectively.   
Figure 5. Myeloma cells down-regulate adiponectin in BMAds. (A) Adiponectin expression in 
human serum. (B) Bone marrow plasma concentrations of adiponectin in our experimental cohort 
of KaLwRij mice. (C) Adiponectin expression in ST2 cells co-cultured with myeloma cell lines 
for 24, 48, and 72 hrs was assessed by immunoblotting. (D) Secreted adiponectin levels in 
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conditioned media from ST2 cells co-cultured with myeloma cell lines for 24, 48, and 72 hrs was 
assessed by immunoblotting. Equal volumes of conditioned media were loaded into each lane. (E) 
Adipoq expression in ST2 cells co-cultured with myeloma cells for 24, 48, and 72 hrs was assessed 
using RT-PCR. (ND = not detectable) Data points represent the mean (±SE) of three independent 
experiments, statistical significance was calculated compared to ST2 alone control (no adipogenic 
media). (F) Adiponectin expression in ST2 cells co-cultured with primary human myeloma cells 
for 24 and 72 hrs was assessed by immunoblotting. 
Figure 6. Myeloma cells reduce BMAd size and number without causing a generalised loss 
in adipokine secretion. (A) Oil red O stained BMAds following 72 hr direct co-culture with 
myeloma cells. Scale bar 50 μm. (B) Eluted Oil red O stain from BMAds following direct co-
culture with JJN-3 or 5TGM1 cells (C) BMAds following 72 hr transwell co-culture with JJN-3 
cells. Scale bar 50 μm. (D) Eluted Oil red O stain from BMAds following transwell co-culture 
with JJN-3 cells. (E) BMAds following 72 hr transwell co-culture with 5TGM1 cells. Scale bar 50 
μM. (F) Eluted Oil red O stain from BMAds following transwell co-culture with 5TGM1 cells. 
Data points represent the mean (±SE) of three independent experiments, statistical significance 
was calculated compared to ST2 alone control. (G) CFD/Adispsin, ADSF/Resistin and 
Nampt/Visfatin expression was assessed by RT-PCR. Data points represent the mean (±SE) of three 
independent experiments, P>0.05, exact P values are shown in supplemental Table 1. 
Figure 7. TNF-alpha down-regulates adiponectin in BMAds. (A) Correlation between bone 
marrow plasma-derived TNF-α and tumour burden from 5TGM1 myeloma-bearing mice. (B)  
Myeloma cells activate ERK1/2 signalling in BMAds. Protein levels of Adiponectin, P-ERK1/2, 
T-ERK1/2, P-JNK, T-JNK, P-P38 MAPK, T-P38 MAPK were assessed by immunoblotting in ST2-
derived BMAds following 24 h treatment with 10ng/ml recombinant TNF-α or co-culture with 
33 
 
5TGM1 cells. (C) Adipoq expression in ST2-derived BMAds following treatment with 10 ng/ml 
mouse recombinant TNF-α for 24, 48 and 72 hrs was measured by RT-PCR. Percentage decrease 
was calculated compared to time point control. (D) Protein levels of adiponectin in conditioned 
media taken from ST2-derived BMAds following 10 ng/ml or 20 ng/ml mouse recombinant TNF-
α treatment for 24, 48 or 72 hrs was assessed by immunoblotting. Equal volumes of conditioned 
media was loaded into each lane. (E) BMAds were treated with 10 ng/ml or 20 ng/ml mouse 
recombinant TNF-α for 72 hrs. Cells were fixed and stained with Oil red O stain. Scale bar 50 μm. 
Stain was eluted and absorbance measured. (F) BMAds were co-cultured with myeloma cells 
(5TGM1) in the presence or absence of an anti-TNF-α neutralising antibody. Secreted adiponectin 
level in the conditioned media was measured. Equal volumes of conditioned media was loaded 
into each lane. (G) Densitometry using imageJ software was used to quantify the level of secreted 
adiponectin shown in F. (H) BMAds were cultured with myeloma cells (5TGM1) in the presence 
or absence of an anti-TNF-α neutralising antibody and Adipoq expression was assessed by RT-
PCR. Data points represent the mean (±SE) of three independent experiments, statistical 
significance was calculated compared to control. (I) BMAds were co-cultured with myeloma cells 
(5TGM1) in the presence or absence of an anti-TNF-α neutralising antibody for 72hrs. BMAds 
were fixed and stained with Oil red O. Stain was eluted and absorbance measured.  Data points 
represent the mean (±SE) of six independent experiments, statistical significance was calculated 
compared to control.  
 
 







Supplemental Data
Supplemental Figure 1. BMAds predominantly locate along the tumour-bone interface.
Formalin fixed sections stained with anti-GFP and Perilipin to visualise BMAd location in the
femur (white circle highlights tumour area, red dotted line denotes bone-tumour interface).
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Supplemental Figure 2. Adipocytes localise to the tumour-bone interface in a human model of
multiple myeloma. NOD/SCID/gamma mice were injected with JJN-3 myeloma cells and developed
aggressive short-term disease. Tumour areas were identified as light patches of cells within the marrow.
Tumour-bone interface is denoted by red dotted line. Scale bar 500 µm. Additional box shows a higher
magnification to show the BMAds surrounding the tumour area (red dotted line denotes tumour-bone
interface). Scale bar 100 µm.
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Supplemental Figure 3. 5TGM1-GFP cells uptake lipid in vivo. Immunofluorescence of 5TGM1-
GFP (green) cells and Lipidtox (red) to visualise adipocytes/lipid. Scale bars 200 µm – 50 µm.
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Figure 4. Myeloma cells decrease adiponectin expression in BMAds but not in WAT-like
adipocytes (A) Adiponectin protein expression was measured in conditioned media taken from
undifferentiated (BMSCs/SCs) and differentiated (BMAds/WAT) ST2 cells and 3T3-L1 cells using
immunoblotting. (B) Adiponectin expression in BMSCs/SCs and BMAds/WAT cultured alone or in
co-culture with 5TGM1 myeloma cells.
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Supplemental Figure 5. TNF-α treatment causes Adipoq mRNA instability in ST2-derived BMAds.
BMAds were treated for 24 hrs with 10ng/ml of TNF-α, Adipoq mRNA stability was assessed by qPCR
following the addition of 10µg/ml actinomycin D for 0, 1, 2, 4 or 6 hours. Data points represent the mean
(±SE) of three independent experiments. Statistical analysis is compared to 0 hrs control.
Supplemental Figure 6. TNF-α treatment decreases Adipoq expression. (A) BMAds were cultured with
myeloma cells (JJN-3) for 48 h in the presence or absence of an anti-TNF-α neutralising antibody, Adipoq
expression was assessed by RT-PCR. Data points represent the mean (±SE) of three independent experiments.
Statistical analysis is compared to control. (B) Viability was measured using Alamar Blue. Results are
expressed as fold change relative to IgG control. Data points represent the mean (±SE) of four independent
experiments. (C) BMAds were cultured with myeloma cells (JJN-3) for 72 hrs in the presence or absence of
an anti-TNF-α neutralising antibody, cells were fixed and stained with Oil red O. The stain was eluted and the
absorbance measured. Data points represent the mean (±SE) of three independent experiments. Statistical
analysis is compared to control.
(C)
(B)(A)
P = 0.02
P = 0.01
P = 0.04
P = 0.004
P = 0.08
P = 0.47
P = 0.32
P = 0.43
0 2 4 6
0.0
0.5
1.0
1.5
Hours (Actinomycin D)
Fr
ac
tio
n 
re
m
ai
ni
ng control
Anti-TNFaP = 0.01
P = 0.96
P = 0.27
P = 0.07
Hours Dunnett’s multiple
comparisons test
Adipsin
(adjusted P 
value)
Resistin
(adjusted P 
value)
Visfatin (adjusted 
P value)
24
Control vs. JJN-3 0.2303 0.9801 0.9981
24
Control vs. MM1.S 0.9913 0.6181 0.7367
24
Control vs. 5TGM1 0.3120 0.9402 0.9856
48
Control vs. JJN-3 0.2011 0.7767 0.5995
48
Control vs. MM1.S 0.5149 0.9986 0.9787
48
Control vs. 5TGM1 0.1744 0.9060 0.8862
72
Control vs. JJN-3 0.4351 0.9956 0.8950
72
Control vs. MM1.S 0.8552 0.9197 0.9997
72
Control vs. 5TGM1 0.4670 0.4469 0.7853
Supplemental Table 1. P values associated with Figure 6G. CFD/Adispsin, ADSF/Resistin and
Nampt/Visfatin expression was assessed by RT-PCR. Data points represent the mean (±SE) of three
independent experiments. Data was analysed using a 2 way ANOVA. statistical significance was
calculated compared to control.
